The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A single arm phase II trial of trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma cancer who are ctDNA and HER2 positive: DECIPHER.
 
Elizabeth Smyth
Employment - HCA International (I)
Honoraria - Bristol-Meyer Squibb; Novartis; Pfizer; SERVIER
Consulting or Advisory Role - Amal Therapeutics; Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb; Merck Serono; Novartis; Roche; SERVIER; Turning Point Therapeutics; Viracta Therapeutics; Zymeworks
Research Funding - Bristol-Meyers Squibb (Inst)
Travel, Accommodations, Expenses - Amgen
 
Daniel Griffiths
Research Funding - Funding for this trial provided by Astra Zeneca (Inst)
 
Kelly Cozens
Research Funding - Funding for this trial was provided by Astra-Zeneca. (Inst)
 
Richard Turkington
Consulting or Advisory Role - Almac Diagnostics
Patents, Royalties, Other Intellectual Property - Patent for the DNA Damage Immune Response Assay in Oesophageal Cancer
 
Rajarshi Roy
Speakers' Bureau - BMS GmbH & Co. KG
Travel, Accommodations, Expenses - SERVIER
 
Sarah Ngan
No Relationships to Disclose
 
Richard Owen
No Relationships to Disclose
 
Kieran Foley
No Relationships to Disclose
 
Robert Waugh
No Relationships to Disclose
 
Ceri Steele
No Relationships to Disclose
 
Dave Chuter
No Relationships to Disclose
 
Chris Hurt
No Relationships to Disclose
 
Gareth Griffiths
Research Funding - Director of Southampton CTU which is core funded by CRUK and part funded by NIHR. As Director I have received funding from Janssen-Cilag, AstraZeneca, Novartis, Astex, Roche, Heartflow, Celldex, BMS, BioNTech, MSD, IntraOp, Synairgen, Blood Cancer UK, Ca (Inst)